Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Rating of “Moderate Buy” by Analysts

Shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) have been assigned a consensus recommendation of “Moderate Buy” from the seven analysts that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 12-month target price among analysts that have covered the stock in the last year is $30.50.

EYPT has been the topic of a number of research reports. HC Wainwright boosted their target price on shares of Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the stock a “buy” rating in a report on Wednesday, August 6th. Chardan Capital reissued a “buy” rating and issued a $27.00 price objective on shares of Eyepoint Pharmaceuticals in a research note on Thursday, August 7th. Royal Bank Of Canada increased their price objective on Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the company an “outperform” rating in a report on Thursday. Mizuho set a $28.00 target price on Eyepoint Pharmaceuticals in a report on Monday, October 20th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Wednesday, October 8th.

Institutional Trading of Eyepoint Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EYPT. Raymond James Financial Inc. lifted its position in shares of Eyepoint Pharmaceuticals by 11.0% in the 2nd quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock worth $112,000 after purchasing an additional 1,177 shares during the period. New York State Common Retirement Fund raised its stake in Eyepoint Pharmaceuticals by 17.3% during the third quarter. New York State Common Retirement Fund now owns 12,214 shares of the company’s stock worth $174,000 after buying an additional 1,800 shares during the last quarter. Arizona State Retirement System raised its stake in Eyepoint Pharmaceuticals by 12.7% during the first quarter. Arizona State Retirement System now owns 16,600 shares of the company’s stock worth $90,000 after buying an additional 1,877 shares during the last quarter. Nisa Investment Advisors LLC lifted its holdings in Eyepoint Pharmaceuticals by 1,636.5% in the second quarter. Nisa Investment Advisors LLC now owns 2,900 shares of the company’s stock valued at $27,000 after buying an additional 2,733 shares during the period. Finally, State of Alaska Department of Revenue bought a new stake in Eyepoint Pharmaceuticals during the third quarter valued at $50,000. Institutional investors and hedge funds own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Trading Up 1.2%

Eyepoint Pharmaceuticals stock opened at $11.21 on Friday. The stock has a 50-day moving average price of $12.83 and a two-hundred day moving average price of $10.26. Eyepoint Pharmaceuticals has a 12 month low of $3.91 and a 12 month high of $14.91. The company has a market capitalization of $772.67 million, a PE ratio of -4.18 and a beta of 1.85.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.08). The firm had revenue of $0.97 million during the quarter, compared to analyst estimates of $3.33 million. Eyepoint Pharmaceuticals had a negative net margin of 337.93% and a negative return on equity of 63.80%. As a group, analysts predict that Eyepoint Pharmaceuticals will post -2.13 earnings per share for the current fiscal year.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.